Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Malaria is a major cause of morbidity and mortality. Immunity is acquired but is suboptimal,
being slow to develop and incomplete. An inadequate understanding of natural immunity …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

Several species of Plasmodium cause a broad spectrum of human disease that range from
nausea and fever to severe anemia, cerebral malaria, and multiorgan failure. In malaria …

Forty years ago, researchers first demonstrated that immunization with irradiated sporozoites
could protect against malaria infection, providing the impetus for the development of a …

Prospects for malaria eradication will be greatly enhanced by an effective vaccine, but
parasite genetic diversity poses a major impediment to malaria vaccine efficacy. In recent …

There have been significant decreases in malaria mortality and morbidity in the last 10-15
years, and the most advanced pre-erythrocytic malaria vaccine, RTS, S, received a positive …

Vaccines are the most powerful public health tools mankind has created, but malaria
parasites are bigger, more complicated, and wilier than the viruses and bacteria that have …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

Malaria is a life‐threatening disease caused by parasites of the P lasmodium genus. In
many parts of the world, the parasites have developed resistance to a number of antimalarial …